Items where authors include "Chau, I"

Article

McNamara, MG, Swain, J, Craig, Z et al. (21 more authors) (2023) NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma. eClinicalMedicine, 60. 102015. ISSN 2589-5370

Athauda, A, Nankivell, M, Langley, RE et al. (6 more authors) (2020) Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03). European Journal of Cancer, 137. pp. 45-56. ISSN 0959-8049

Craig, Z orcid.org/0000-0001-9930-6648, Swain, J, Batman, E et al. (16 more authors) (2020) NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open, 10 (2). e034527. ISSN 2044-6055

Glynne-Jones, R, Hall, MR, Lopes, A et al. (15 more authors) (2018) BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC). Heliyon, 4 (9). e00804. ISSN 2405-8440

Davidson, M, Chau, I, Cunningham, D et al. (5 more authors) (2017) Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. World Journal of Gastrointestinal Oncology, 9 (8). pp. 333-340. ISSN 1948-5204

Glynne-Jones, R, Hava, N, Goh, V et al. (18 more authors) (2015) Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. BMC Cancer, 15. 764. ISSN 1471-2407

Middleton, G, Brown, S, Lowe, C et al. (17 more authors) (2013) A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). European Journal of Cancer, 49 (16). 3507 - 3516. ISSN 0959-8049

Seymour, MT, Brown, SR, Middleton, G et al. (18 more authors) (2013) Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. The Lancet Oncology, 14 (8). 749 - 759. ISSN 1470-2045

Proceedings Paper

Athauda, A, Nankivell, MG, Langley, RE et al. (17 more authors) (2019) Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC & ST03). In: Journal of Clinical Oncology. Annual Meeting of the American Society of Clinical Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, IL, USA. American Society of Clinical Oncology (ASCO) .